Logo

CRISPR

ElevateBio Inks Deal to Use Amazon Web Services' AI Tools for CRISPR Drug Development

ElevateBio has entered into a multiyear collaboration with Amazon's cloud arm to identify treatment targets and new CRISPR systems.

Intellia Therapeutics' In Vivo CRISPR Drug Could Offer One-Time Fix for ATTR Amyloidosis
Premium

A Phase III trial evaluating nex-z in transthyretin amyloidosis with cardiomyopathy is underway, with plans for another focused on polyneuropathy.

NICE Recommends Vertex, CRISPR Therapeutics' Casgevy for Sickle Cell Under Managed Access Deal

The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

Intellia Therapeutics Doses First Patient in Phase III Hereditary Angioedema Trial of CRISPR Drug

The company expects to submit a biologics license application for NTLA-2002 in 2026 and potentially launch it in the US in 2027.

Intellia Readying for Commercial Activities, First Product Launch in 2027
Premium

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and transthyretin amyloidosis.

Jan 10, 2025

Intellia Cuts AATD Gene Insertion Program, 27 Percent of Workforce in Strategic Reorganization

Dec 18, 2024

Gene Therapy in 2024: 'Persistent' Approvals, Layoffs, and In Vivo Moving Toward the Clinic
Premium

Dec 13, 2024

Editas Medicine Lays off 65 Percent of Workforce; Drops Sickle Cell, TDT Candidate Reni-Cel

Dec 11, 2024

ASH24 Gene Therapy Readouts in Sickle Cell, TDT: Editas, Vertex, Beam, Bluebird Bio
Premium

Nov 4, 2024

HuidaGene Therapeutics to Launch Wet AMD CRISPR RNA-Editing Trial in US

Oct 23, 2024

Editas Seeking Partner or Licensing Deal for Lead Sickle Cell, TDT Gene-Editing Treatment Candidate

Oct 8, 2024

Intellia Starts Phase III Hereditary Angioedema Trial for CRISPR Gene-Editing Therapy

Oct 4, 2024

In Brief This Week: Modalis, Otsuka, CSL Behring, Papillon, Anixa Biosciences, PathAI

Sep 24, 2024

KSQ Therapeutics Gets FDA Clearance to Begin Phase I/II Trial of TIL Therapy KSQ-004EX

Sep 24, 2024

Genetic Counselors Can Help Patients Sort Concerns, Set Expectations for Gene Therapies
Premium

Sep 17, 2024

Intellia Therapeutics Testing Gene Insertion Therapy for AATD-Linked Lung Disease
Premium

Jul 24, 2024

Editas Medicine Continues to Seek Partner for Promising LCA10 CRISPR Gene Therapy
Premium

Jun 12, 2024

KSQ Therapeutics Treats First Patient in Phase I/II Trial of Engineered TIL Therapy

Jun 4, 2024

FDA Platform Designation Program Could Ease Path to Market for Gene-Editing Therapies

May 2, 2024

Sickle Cell Gene Therapy Fertility Risks Spur Calls for Changes Allowing Industry Support Services

Apr 25, 2024

Mammoth Biosciences to Receive $100M Upfront in Therapeutic CRISPR Gene Editing Deal With Regeneron

Apr 4, 2024

Drugmakers Clamor to Prove 'Lp(a) Hypothesis' in Cardiovascular Disease
Premium

Mar 26, 2024

Volastra Therapeutics Inks Two New Deals to ID Biomarkers for KIF18A Inhibitor Patient Selection

Mar 18, 2024

Intellia Therapeutics Begins In Vivo Gene-Editing Therapy Dosing in Pivotal ATTR Amyloidosis Trial

Mar 14, 2024

Anocca, EmendoBio Partner to Advance CRISPR Gene-Edited TCR-T Therapies